GlassScriptPhysician profile
Karleung S Siu
NPI 1649417437
$2,485.64
in general payments reported to CMS, 2019-2025
27 companies · $774 in 2025
The $774 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $912 · 2021: $349 · 2022: $141 · 2023: $99.31 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $591 · Long Term Medical Supply Or Device Loan: $199 · Education: $82.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.79 |
| Long Term Medical Supply Or Device Loan | $199.40 |
| Education | $82.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $972.15 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $287.35 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $163.12 | 2019-2025 | Keytruda, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $129.79 | 2019-2025 | Lynparza, Tagrisso |
| Seagen INC. | $116.94 | 2020-2021 | |
| Pfizer INC. | $116.45 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $99.00 | 2021 | |
| Incyte Corporation | $98.20 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.48 | 2019-2025 | |
| Janssen Biotech, INC. | $65.87 | 2022-2025 | Darzalex, Talvey, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $52.52 | 2019-2025 | Opdivo |
| Eisai INC. | $40.76 | 2019-2020 | |
| Lilly USA, LLC | $40.30 | 2025 | Verzenio, Jaypirca |
| Emd Serono, INC. | $34.31 | 2019-2025 | |
| Daiichi Sankyo INC. | $31.47 | 2025 | Datroway |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $29.45 | 2019-2020 | |
| Taiho Oncology, INC. | $23.05 | 2025 | |
| Pharmaessentia USA Corporation | $19.00 | 2025 | Besremi |
| Genentech USA, INC. | $17.48 | 2025 | Venclexta |
| Beone Medicines USA, INC. | $16.37 | 2025 | Brukinsa |
| Janssen Pharmaceuticals, INC | $16.32 | 2023 | Xarelto |
| Gilead Sciences, INC. | $14.70 | 2019 | |
| Astellas Pharma US INC | $14.54 | 2019 | |
| Tesaro, INC. | $11.02 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karleung Siu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.